TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21130386

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 80 μg
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 160 μg
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 17034536

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolaevulinate (MAL)-photodynamic therapy (PDT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Subject and investigator preferences
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cosmetic outcome
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Skin discomfort and adverse events
Number of subjects: 119
Study: 14557158

Group type: EXPERIMENTAL
Intervention: Intervention period with test charge information on emergency department records
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Control period for high test users
Number of subjects: 3198

Group type: COMPARATOR
Intervention: Control period for low test users
Number of subjects: 3198

Group type: EXPERIMENTAL
Intervention: Low test users vs high test users
Number of subjects: 3198
Study: 10914048

Group type: EXPERIMENTAL
Intervention: Diazepam premedication (oral, 1 hour before BMP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo premedication (oral, 1 hour before BMP)
Number of subjects: 16
Study: 8623975

Group type: EXPERIMENTAL
Intervention: Nalbuphine 2.5 mg/h, PSA nalbuphine 1 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Naloxone 50 micrograms/hr, PSA saline
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Naloxone 50 micrograms/h, PSA naloxone 40 micrograms
Number of subjects: 51
Study: 1564028

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: lithium carbonate alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: methylphenidate and lithium carbonate in combination
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 3935644

Group type: EXPERIMENTAL
Intervention: Pelletized cromolyn (cromolyn sodium, 20 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cromolyn blend (cromolyn sodium, 20 mg + lactose, 20 mg)
Number of subjects: 100
Study: 31707149

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 81 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 325 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg) twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) placebo
Number of subjects: 49
Study: 28222577

Group type: EXPERIMENTAL
Intervention: SUPP: 500 mg alpha glycerophosphocholine [AGPC], 250 mg uridine‐5'‐monophosphate, and 1500 mg DHA
Number of subjects: 20

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 20
Study: 25785788

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for depressed adolescents (IPT‐A)
Number of subjects: 32
Study: 24481133

Group type: EXPERIMENTAL
Intervention: Beetroot juice supplementation (0.5 l/day organic beetroot juice containing about 5.5 mmol of NO₃⁻)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control swimming test (CSW)
Number of subjects: 14
Study: 21978203

Group type: EXPERIMENTAL
Intervention: Numeracy skills at level 2 or above
Number of subjects: 112

Group type: COMPARATOR
Intervention: Numeracy skills below level 2
Number of subjects: 112
Study: 20353024

Group type: EXPERIMENTAL
Intervention: Jianpi Tiaogan Wenshen Recipe (JTWR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pinaverium bromide tablet (PVB)
Number of subjects: 80
Study: 18959094

Group type: EXPERIMENTAL
Intervention: Diuretics (particularly loop diuretics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists (spironolactone and eplerenone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study: 16087795

Group type: EXPERIMENTAL
Intervention: GM‐CSF (10 microg/kg, subcutaneously applied for 14 days, total of 7 injections)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 40
Study: 12483770

Group type: EXPERIMENTAL
Intervention: Zhang and Boos extension of the standard CMH statistic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CMH statistic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bootstrap method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Method using design effect to reduce effective sample size
Number of subjects: 0
Study: 10362041

Group type: EXPERIMENTAL
Intervention: Metal spacer (Nebuchamber)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Plastic spacer (Babyhaler)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Plastic spacer (Volumatic)
Number of subjects: 33
Study: 7742149

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Renin inhibitor
Number of subjects: 64
Study: 1836569

Group type: EXPERIMENTAL
Intervention: Cefazolin or cefotaxime (3 doses of 1 g administered 8-hourly)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Ceftriaxone (1 single dose of 1 g)
Number of subjects: 1254
Study: 6112844

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta1-selective blockade
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beta-blockers (general)
Number of subjects: 10
Study: 31155691

Group type: EXPERIMENTAL
Intervention: Crowdsourcing interventions
Number of subjects: 15
Study: 28286985

Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mindfulness interventions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hypnosis interventions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Various relaxation interventions
Number of subjects: 5
Study: 25323620

Group type: EXPERIMENTAL
Intervention: High-intensity endurance and strength training (60 min, three times a week, for 20 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard postoperative care)
Number of subjects: 61
Study: 23775366

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 357

Group type: COMPARATOR
Intervention: Continued medical management
Number of subjects: 357
Study: 21241214

Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine (ED-NVP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single-dose nevirapine (SD-NVP)
Number of subjects: 43
Study: 19293532

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Plasma BH4 levels
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Plasma BH2 levels
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: BH4/BH2 ratio
Number of subjects: 163
Study: 16890682

Group type: EXPERIMENTAL
Intervention: Uriston (P. niruri extract) 2 gm daily for at least 3 months (group 1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 150
Study: 14520089

Group type: EXPERIMENTAL
Intervention: No antibiotics for AOM
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo for recurrent AOM
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No treatment for OME after untreated AOM
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No treatment for OME of unknown duration
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No treatment for chronic OME
Number of subjects: 63
Study: 10912758

Group type: EXPERIMENTAL
Intervention: Trp allele presence in white subjects
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Trp allele presence in white subjects with multivariate adjustment
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Trp allele presence in older white subjects with specific risk factors
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Trp allele presence in black subjects
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Trp allele presence in black subjects with multivariate adjustment
Number of subjects: 1394
Study: 9130746

Group type: EXPERIMENTAL
Intervention: Tubal embryo transfer
Number of subjects: 138

Group type: COMPARATOR
Intervention: Uterine transfer
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups (tubal and uterine transfer)
Number of subjects: 138
Study: 8406967

Group type: EXPERIMENTAL
Intervention: Post space prepared immediately after canal obturation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Post space prepared after 1 week of storage in 100% relative humidity at 37 degrees C
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no post space preparation)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Post space preparation (both intervention groups)
Number of subjects: 72
Study: 3534902

Group type: EXPERIMENTAL
Intervention: 3 X 60 mg Eburnamonine per day (n = 25)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1 X 60 mg Eburnamonine per day (n = 25)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30501388

Group type: EXPERIMENTAL
Intervention: Rotator cuff strengthening plus coactivation with pectoralis major and latissimus dorsi recruitment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Strengthening of the scapular and rotator cuff muscles
Number of subjects: 42
Study: 29781943

Group type: EXPERIMENTAL
Intervention: Sterilized in autoclave (40 rods)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sterilized using hydrogen peroxide (40 rods)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unsterilized (4 rods)
Number of subjects: 44
Study: 27376867

Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of an e‐alert, care bundle and education programme
Number of subjects: 0
Study: 24761922

Group type: EXPERIMENTAL
Intervention: Recommendation of faecal occult blood test (FOBT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Barriers to colorectal cancer screening
Number of subjects: 116
Study: 21479957

Group type: EXPERIMENTAL
Intervention: Low-cadence interval training (Int(60), 60 rev min(‐1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-cadence interval training (Int(100), 100 rev min(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 18
Study: 20383685

Group type: EXPERIMENTAL
Intervention: Passive self‐assisted range of motion exercise associated with continuous passive motion (CPM) for 2 hours per day for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Passive self‐assisted range of motion exercise alone
Number of subjects: 100
Study: 18846701

Group type: EXPERIMENTAL
Intervention: Plant sterol (2.5 g/d)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Plant stanol (2.5 g/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control margarine (no added plant sterols or stanols)
Number of subjects: 54
Study: 15914133

Group type: EXPERIMENTAL
Intervention: Three gels containing different amounts of N-9 per dose
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Suppository
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Film
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Overall acceptability of all five spermicides
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Overall acceptability
Number of subjects: 1536
Study: 12191837

Group type: EXPERIMENTAL
Intervention: 25 g of glucose administered immediately before presentation of a word list
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 g of glucose administered immediately after presentation of a word list
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 g of glucose administered 15 min before learning the word list
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartame solution (control)
Number of subjects: 0
Study: 11904624

Group type: EXPERIMENTAL
Intervention: Sucrose on a pacifier
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mogen procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gomco procedure
Number of subjects: 0
Study: 9531185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.01 microg/kg/min)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.05 microg/kg/min)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.1 microg/kg/min)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo (diabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.01 microg/kg/min) (diabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.05 microg/kg/min) (diabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.1 microg/kg/min) (diabetic patients)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo (nondiabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.01 microg/kg/min) (nondiabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.05 microg/kg/min) (nondiabetic patients)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Anaritide (0.1 microg/kg/min) (nondiabetic patients)
Number of subjects: 247
Study: 7979152

Group type: EXPERIMENTAL
Intervention: Erythrocyte aggregation in patients with hemorrhoidal disease
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with acute hemorrhoid problems
Number of subjects: 62
Study: 2567265

Group type: EXPERIMENTAL
Intervention: SKF 94482 200 mg at 07:30
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SKF 94482 200 mg at 17:30
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SKF 94482 200 mg at 21:30
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30776909

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Number of subjects: 40
Study: 28718527

Group type: EXPERIMENTAL
Intervention: Intralesional Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intralesional Hyaluronic Acid (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks
Number of subjects: 0
Study: 25444633

Group type: EXPERIMENTAL
Intervention: Animated biofeedback and pelvic floor muscle (PFM) exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 50
Study: 24262620

Group type: EXPERIMENTAL
Intervention: ANGIOGUARD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mo.Ma
Number of subjects: 60
Study: 21844178

Group type: EXPERIMENTAL
Intervention: Home telehealth service using a web portal for videoconferencing and electronic messaging; duration: 9 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 99
Study: 18924040

Group type: EXPERIMENTAL
Intervention: Mesh techniques
Number of subjects: 1513008

Group type: COMPARATOR
Intervention: Non-mesh techniques
Number of subjects: 1513008
Study: 16820037

Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bovine-derived xenograft (BDX) in combination with collagen membrane (BG)
Number of subjects: 22
Study: 14559891

Group type: EXPERIMENTAL
Intervention: Aprepitant 375 mg before cisplatin and 250 mg on days 2 to 5 (n = 35)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg before cisplatin and 80 mg on days 2 to 5 (n = 81)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo before cisplatin on days 2 to 5 (n = 86)
Number of subjects: 202
Study: 10840297

Group type: EXPERIMENTAL
Intervention: Triple therapy (10-day proton pump inhibitor-based triple therapy)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Dual antibiotic therapy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Antral histology
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Antral culture
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Antral biopsies without body biopsies
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Histologic examination of antral biopsies
Number of subjects: 301
Study: 9166175

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 8466096

Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg, once daily (QD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Terfenadine, 60 mg, twice daily (BID)
Number of subjects: 160
Study: 31801388

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate (10mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nepafenac (1mg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone acetate and nepafenac)
Number of subjects: 60
Study: 31113830

Group type: EXPERIMENTAL
Intervention: HTX-011
Number of subjects: 412

Group type: COMPARATOR
Intervention: bupivacaine HCl
Number of subjects: 412

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 412
Study: 28348183

Group type: EXPERIMENTAL
Intervention: Pregnant+ app and standard care
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 230
Study: 26307570

Group type: EXPERIMENTAL
Intervention: CSL112 1.7 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CSL112 3.4 g
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CSL112 6.8 g
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CSL112 (all doses)
Number of subjects: 45
Study: 24261057

Group type: COMPARATOR
Intervention: Endurance Training Program (ETP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Coordination Training Program (CTP)
Number of subjects: 29
Study: 20870337

Group type: EXPERIMENTAL
Intervention: High intensity cognitive therapy with nicotine replacement therapy (NRT)
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: High intensity cognitive therapy without nicotine replacement therapy (NRT)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Follow up in clinics (NRT group)
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Follow up via telephone sessions (NRT group)
Number of subjects: 1843
Study: 19615208

Group type: EXPERIMENTAL
Intervention: Albumin administration (100 ml 20% human albumin daily for 3 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Saline administration (100 ml saline daily for 3 days)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 16960162

Group type: EXPERIMENTAL
Intervention: Soybean oil (SO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-saturated fatty acid soybean oil (LoSFA-SO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-oleic acid soybean oil (HiOleic-SO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-alpha-linolenic acid soybean oil (LoALA-SO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Partially hydrogenated soybean oil (Hydrog-SO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unhydrogenated soybean oils (SO, LoSFA-SO, HiOleic-SO, LoALA-SO)
Number of subjects: 30
Study: 15175800

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min combined with VKA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) combined with VKA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses up to 2 microg/kg/min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ecarin Clotting Time (ECT)
Number of subjects: 39
Study: 15635852

Group type: EXPERIMENTAL
Intervention: High intensity training (Group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low intensity training (Group B)
Number of subjects: 22
Study: 9468763

Group type: EXPERIMENTAL
Intervention: Reduced-fat group
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study: 7945491

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 122

Group type: COMPARATOR
Intervention: High-dose prednisone
Number of subjects: 122

Group type: COMPARATOR
Intervention: Immunosuppressive other than cyclophosphamide
Number of subjects: 122

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 122

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 122
Study: 3556129

Group type: EXPERIMENTAL
Intervention: 24 mEq of Slow-K given as 8 mEq/tablet tid
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 mEq of K-Tab given as 10 mEq/tablet tid
Number of subjects: 20
Study: 30241488

Group type: EXPERIMENTAL
Intervention: VivaSight™‐SL tube (VST)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional intubation under direct laryngoscopy (DL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VST
Number of subjects: 54

Group type: COMPARATOR
Intervention: DL
Number of subjects: 54
Study: 27333950

Group type: EXPERIMENTAL
Intervention: Loving-Kindness Meditation (LKM)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Light Exercise (LE)
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Both courses (LKM and LE)
Number of subjects: 809
Study: 24225560

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG)
Number of subjects: 14
Study: 23643522

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc + ALA supplementation (2 g/day flaxseed oil)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: IL-6
Number of subjects: 48

Group type: COMPARATOR
Intervention: CRP
Number of subjects: 48

Group type: COMPARATOR
Intervention: TNF-α
Number of subjects: 48
Study: 21336433

Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables (six servings each per day) during the first postoperative month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60